Post–hematopoietic stem cell transplantation immune-mediated anemia: a literature review and novel therapeutics

International Society of Blood Transfusion Hows, 1986, Donor-derived red blood cell antibodies and immune hemolysis after allogeneic bone marrow transplantation, Blood., 67, 177, 10.1182/blood.V67.1.177.177 Rowley, 2011, Red blood cell-incompatible allogeneic hematopoietic progenitor cell transplantation, Bone Marrow Transplant., 46, 1167, 10.1038/bmt.2011.135 Griffith, 2005, Persistence of recipient plasma cells and anti-donor isohaemagglutinins in patients with delayed donor erythropoiesis after major ABO incompatible non-myeloablative haematopoietic cell transplantation, Br J Haematol., 128, 668, 10.1111/j.1365-2141.2005.05364.x Stussi, 2002, Consequences of ABO incompatibility in allogeneic hematopoietic stem cell transplantation, Bone Marrow Transplant., 30, 87, 10.1038/sj.bmt.1703621 Allen, 2018, How we evaluate red blood cell compatibility and transfusion support for patients with sickle cell disease undergoing hematopoietic progenitor cell transplantation, Transfusion., 58, 2483, 10.1111/trf.14871 Ting, 1987, Red cell alloantibodies produced after bone marrow transplantation, Transfusion., 27, 145, 10.1046/j.1537-2995.1987.27287150186.x Young, 2001, Immune hemolysis involving non-ABO/RhD alloantibodies following hematopoietic stem cell transplantation, Bone Marrow Transplant., 27, 1305, 10.1038/sj.bmt.1703074 Abou-Elella, 1995, Low incidence of red cell and HLA antibody formation by bone marrow transplant patients, Transfusion., 35, 931, 10.1046/j.1537-2995.1995.351196110898.x de La Rubia, 2001, Development of non-ABO RBC alloantibodies in patients undergoing allogeneic HPC transplantation. Is ABO incompatibility a predisposing factor?, Transfusion., 41, 106, 10.1046/j.1537-2995.2001.41010106.x Flegel, 2015, Pathogenesis and mechanisms of antibody-mediated hemolysis, Transfusion., 55, S47, 10.1111/trf.13147 Filipovich, 2005, National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report, Biol Blood Marrow Transplant., 11, 945, 10.1016/j.bbmt.2005.09.004 Couriel, 2006, Ancillary therapy and supportive care of chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working Group report, Biol Blood Marrow Transplant., 12, 375, 10.1016/j.bbmt.2006.02.003 Szanto, 2020, Predictors for autoimmune cytopenias after allogeneic hematopoietic cell transplantation in children, Biol Blood Marrow Transplant., 26, 114, 10.1016/j.bbmt.2019.07.022 Stowell, 2012, Initiation and regulation of complement during hemolytic transfusion reactions, Clin Dev Immunol., 2012, 307093, 10.1155/2012/307093 Rowley, 2000, Transplantation of ABO-incompatible bone marrow and peripheral blood stem cell components, Bone Marrow Transplant., 26, 749, 10.1038/sj.bmt.1702572 Curley, 2012, Outcomes after major or bidirectional ABO-mismatched allogeneic hematopoietic progenitor cell transplantation after pretransplant isoagglutinin reduction with donor-type secretor plasma with or without plasma exchange, Transfusion., 52, 291, 10.1111/j.1537-2995.2011.03295.x Hirokawa, 2013, Efficacy and long-term outcome of treatment for pure red cell aplasia after allogeneic stem cell transplantation from major ABO-incompatible donors, Biol Blood Marrow Transplant., 19, 1026, 10.1016/j.bbmt.2013.04.004 Gmür, 1990, Pure red cell aplasia of long duration complicating major ABO-incompatible bone marrow transplantation, Blood., 75, 290, 10.1182/blood.V75.1.290.290 Worel, 2000, Regeneration of erythropoiesis after related- and unrelated-donor BMT or peripheral blood HPC transplantation: a major ABO mismatch means problems, Transfusion., 40, 543, 10.1046/j.1537-2995.2000.40050543.x Damodar, 2017, Donor-to-recipient ABO mismatch does not impact outcomes of allogeneic hematopoietic cell transplantation regardless of graft source, Biol Blood Marrow Transplant., 23, 795, 10.1016/j.bbmt.2017.02.009 Kanda, 2009, Impact of ABO mismatching on the outcomes of allogeneic related and unrelated blood and marrow stem cell transplantations for hematologic malignancies: IPD-based meta-analysis of cohort studies, Transfusion., 49, 624, 10.1111/j.1537-2995.2008.02043.x Logan, 2015, ABO mismatch is associated with increased nonrelapse mortality after allogeneic hematopoietic cell transplantation, Biol Blood Marrow Transplant., 21, 746, 10.1016/j.bbmt.2014.12.036 Canaani, 2017, Impact of ABO incompatibility on patients’ outcome after haploidentical hematopoietic stem cell transplantation for acute myeloid leukemia - a report from the Acute Leukemia Working Party of the EBMT, Haematologica., 102, 1066, 10.3324/haematol.2016.160804 Bolan, 2001, Delayed donor red cell chimerism and pure red cell aplasia following major ABO-incompatible nonmyeloablative hematopoietic stem cell transplantation, Blood., 98, 1687, 10.1182/blood.V98.6.1687 Worel, 2003, ABO mismatch increases transplant-related morbidity and mortality in patients given nonmyeloablative allogeneic HPC transplantation, Transfusion., 43, 1153, 10.1046/j.1537-2995.2003.00465.x Brierley, 2015, Impact of ABO blood group mismatch in alemtuzumab-based reduced-intensity conditioned haematopoietic SCT, Bone Marrow Transplant., 50, 931, 10.1038/bmt.2015.51 Dehn, 2019, Selection of unrelated donors and cord blood units for hematopoietic cell transplantation: guidelines from the NMDP/CIBMTR, Blood., 134, 924, 10.1182/blood.2019001212 Buckner, 1978, ABO-incompatible marrow transplants, Transplantation., 26, 233, 10.1097/00007890-197810000-00006 Bensinger, 1982, ABO-incompatible marrow transplants, Transplantation., 33, 427, 10.1097/00007890-198204000-00017 Benjamin, 1999, ABO incompatibility as an adverse risk factor for survival after allogeneic bone marrow transplantation, Transfusion., 39, 179, 10.1046/j.1537-2995.1999.39299154733.x Quek, 2019, Donor-type fresh frozen plasma is effective in preventing hemolytic reaction in major ABO incompatible allogeneic stem cell transplant, Transfusion., 59, 335, 10.1111/trf.15053 Mehta, 2021, Pre-transplant donor-type red cell transfusion is a safe and effective strategy to reduce isohemagglutinin titers and prevent donor marrow infusion reactions in major ABO-mismatched transplants, Ann Hematol., 100, 2071, 10.1007/s00277-021-04571-3 Scholl, 2005, Safety and impact of donor-type red blood cell transfusion before allogeneic peripheral blood progenitor cell transplantation with major ABO mismatch, Transfusion., 45, 1676, 10.1111/j.1537-2995.2005.00578.x Bolan, 2001, Massive immune haemolysis after allogeneic peripheral blood stem cell transplantation with minor ABO incompatibility, Br J Haematol., 112, 787, 10.1046/j.1365-2141.2001.02587.x Toren, 1996, Passenger B-lymphocyte-induced severe hemolytic disease after allogeneic peripheral blood stem cell transplantation, Blood., 87, 843, 10.1182/blood.V87.2.843.bloodjournal872843 Noborio, 2003, Massive immune hemolysis after non-myeloablative allogeneic peripheral blood stem cell transplantation with minor ABO-incompatibility, Leuk Lymphoma., 44, 357, 10.1080/1042819021000030036 Worel, 2002, Severe immune hemolysis after minor ABO-mismatched allogeneic peripheral blood progenitor cell transplantation occurs more frequently after nonmyeloablative than myeloablative conditioning, Transfusion., 42, 1293, 10.1046/j.1537-2995.2002.00209.x Rosenthal, 1988, Suppression of B cell function by methotrexate and trimetrexate. Evidence for inhibition of purine biosynthesis as a major mechanism of action, J Immunol., 141, 410, 10.4049/jimmunol.141.2.410 Vaezi, 2017, ABO incompatibility and hematopoietic stem cell transplantation outcomes, Int J Hematol Oncol Stem Cell Res., 11, 139 Ma, 2020, Impact of ABO incompatibility on outcomes after haploidentical hematopoietic stem cell transplantation for severe aplastic anemia, Bone Marrow Transplant., 55, 1068, 10.1038/s41409-020-0779-7 Grube, 2016, ABO blood group antigen mismatch has an impact on outcome after allogeneic peripheral blood stem cell transplantation, Clin Transplant., 30, 1457, 10.1111/ctr.12840 Ludajic, 2009, Minor ABO-mismatches are risk factors for acute graft-versus-host disease in hematopoietic stem cell transplant patients, Biol Blood Marrow Transplant., 15, 1400, 10.1016/j.bbmt.2009.07.002 Booth, 2013, Clinical guide to ABO-incompatible allogeneic stem cell transplantation, Biol Blood Marrow Transplant., 19, 1152, 10.1016/j.bbmt.2013.03.018 Heddle, 1995, A prospective study to determine the frequency and clinical significance of alloimmunization post-transfusion, Br J Haematol., 91, 1000, 10.1111/j.1365-2141.1995.tb05425.x Hoeltge, 1995, Multiple red cell transfusions and alloimmunization. Experience with 6996 antibodies detected in a total of 159,262 patients from 1985 to 1993, Arch Pathol Lab Med., 119, 42 Seyfried, 1990, Analysis of immune response to red blood cell antigens in multitransfused patients with different diseases, Mater Med Pol., 22, 21 Higgins, 2008, Stochastic modeling of human RBC alloimmunization: evidence for a distinct population of immunologic responders, Blood., 112, 2546, 10.1182/blood-2008-03-146415 Klumpp, 1991, Immunohematologic complications of bone marrow transplantation, Bone Marrow Transplant., 8, 159 López, 1998, Severe hemolytic anemia due to multiple red cell alloantibodies after an ABO-incompatible allogeneic bone marrow transplant, Transfusion., 38, 247, 10.1046/j.1537-2995.1998.38398222868.x Kay, 2016, Anti-Jka that are detected by solid-phase red blood cell adherence but missed by gel testing can cause hemolytic transfusion reactions, Transfusion., 56, 2973, 10.1111/trf.13782 Leo, 2000, Passenger lymphocyte syndrome with severe hemolytic anemia due to an anti-Jk(a) after allogeneic PBPC transplantation, Transfusion., 40, 632, 10.1046/j.1537-2995.2000.40060632.x Petz, 2005, Immune hemolysis associated with transplantation, Semin Hematol., 42, 145, 10.1053/j.seminhematol.2005.05.017 Franchini, 2004, Non-ABO red blood cell alloantibodies following allogeneic hematopoietic stem cell transplantation, Bone Marrow Transplant., 33, 1169, 10.1038/sj.bmt.1704524 Campbell-Lee, 2018, Red blood cell alloimmunization in sickle cell disease: assessment of transfusion protocols during two time periods, Transfusion., 58, 1588, 10.1111/trf.14588 Hindawi, 2020, The value of transfusion of phenotyped blood units for thalassemia and sickle cell anemia patients at an academic center, Transfusion., 60, S15, 10.1111/trf.15682 Chou, 2013, High prevalence of red blood cell alloimmunization in sickle cell disease despite transfusion from Rh-matched minority donors, Blood., 122, 1062, 10.1182/blood-2013-03-490623 Allen, 2017, Immunohaematological complications in patients with sickle cell disease after haemopoietic progenitor cell transplantation: a prospective, single-centre, observational study, Lancet Haematol., 4, e553, 10.1016/S2352-3026(17)30196-5 Nickel, 2020, The impact of pre-existing HLA and red blood cell antibodies on transfusion support and engraftment in sickle cell disease after nonmyeloablative hematopoietic stem cell transplantation from HLA-matched sibling donors: a prospective, single-center, observational study, EClinicalMedicine., 24, 100432, 10.1016/j.eclinm.2020.100432 Thompson, 2011, Red cell alloimmunization in a diverse population of transfused patients with thalassaemia, Br J Haematol., 153, 121, 10.1111/j.1365-2141.2011.08576.x Datta, 2015, Frequency of red cell alloimmunization and autoimmunization in thalassemia patients: a report from eastern India, Adv Hematol., 2015, 610931, 10.1155/2015/610931 Waldis, 2021, Rh alloimmunization in chronically transfused patients with thalassemia receiving RhD, C, E, and K matched transfusions, Blood Adv., 5, 737, 10.1182/bloodadvances.2020003732 El-Beshlawy, 2020, A study of red blood cell alloimmunization and autoimmunization among 200 multitransfused Egyptian β thalassemia patients, Sci Rep., 10, 21079, 10.1038/s41598-020-78333-y Hönig, 2010, Successful hematopoietic stem-cell transplantation in a patient with chronic granulomatous disease and McLeod phenotype sensitized to Kx and K antigens, Bone Marrow Transplant., 45, 209, 10.1038/bmt.2009.115 Kordes, 2008, Successful donor-lymphocyte infusion for extreme immune-hemolysis following unrelated BMT in a patient with X-linked chronic granulomatous disease and McLeod phenotype, Bone Marrow Transplant., 42, 219, 10.1038/bmt.2008.159 Kim, 2013, Major non-ABO incompatibility caused by anti-Jk(a) in a patient before allogeneic hematopoietic stem cell transplantation, Immunohematology., 29, 11, 10.21307/immunohematology-2019-117 Passweg, 2015, Hematopoietic SCT in Europe 2013: recent trends in the use of alternative donors showing more haploidentical donors but fewer cord blood transplants, Bone Marrow Transplant., 50, 476, 10.1038/bmt.2014.312 Lasalle-Williams, 2011, Extended red blood cell antigen matching for transfusions in sickle cell disease: a review of a 14-year experience from a single center (CME), Transfusion., 51, 1732, 10.1111/j.1537-2995.2010.03045.x Casas, 2015, Changing practice: red blood cell typing by molecular methods for patients with sickle cell disease, Transfusion., 55, 1388, 10.1111/trf.12987 Fasano, 2016, Red blood cell antigen genotyping for sickle cell disease, thalassemia, and other transfusion complications, Transfus Med Rev., 30, 197, 10.1016/j.tmrv.2016.05.011 Liu, 2013, ABO chimerism determined by real-time polymerase chain reaction analysis after ABO-incompatible haematopoietic stem cell transplantation, Blood Transfus., 11, 43 Barcellini, 2019, Management of refractory autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation: current perspectives, J Blood Med., 10, 265, 10.2147/JBM.S190327 Miller, 2020, Autoimmune cytopenias (AIC) following allogeneic haematopoietic stem cell transplant for acquired aplastic anaemia: a joint study of the Autoimmune Diseases and Severe Aplastic Anaemia Working Parties (ADWP/SAAWP) of the European Society for Blood and Marrow Transplantation (EBMT), Bone Marrow Transplant., 55, 441, 10.1038/s41409-019-0680-4 Horn, 1999, Autoimmune hemolytic anemia in patients with SCID after T cell-depleted BM and PBSC transplantation, Bone Marrow Transplant., 24, 1009, 10.1038/sj.bmt.1702011 Ahmed, 2015, The incidence of autoimmune hemolytic anemia in pediatric hematopoietic stem cell recipients post-first and post-second hematopoietic stem cell transplant, Pediatr Transplant., 19, 391, 10.1111/petr.12455 Kruizinga, 2018, Risk factors, treatment, and immune dysregulation in autoimmune cytopenia after allogeneic hematopoietic stem cell transplantation in pediatric patients, Biol Blood Marrow Transplant., 24, 772, 10.1016/j.bbmt.2017.12.782 O’Brien, 2004, Autoimmune haemolytic anaemia complicating haematopoietic cell transplantation in paediatric patients: high incidence and significant mortality in unrelated donor transplants for non-malignant diseases, Br J Haematol., 127, 67, 10.1111/j.1365-2141.2004.05138.x Faraci, 2014, Autoimmune hematological diseases after allogeneic hematopoietic stem cell transplantation in children: an Italian multicenter experience, Biol Blood Marrow Transplant., 20, 272, 10.1016/j.bbmt.2013.11.014 Garratty, 2004, Autoantibodies induced by blood transfusion, Transfusion., 44, 5, 10.1111/j.0041-1132.2004.00658.x González-Vicent, Autoimmune hemolytic anemia (AIHA) following allogeneic hematopoietic stem cell transplantation (HSCT): a retrospective analysis and a proposal of treatment on behalf of the Grupo Español De Trasplante de Medula Osea en Niños (GETMON) and the Grupo Español de Trasplante Hematopoyetico (GETH) [published online ahead of print on 3 March 2018], Transfus Med Rev. Adams, 2010, Self-limited hemolysis due to anti-D passenger lymphocyte syndrome in allogeneic hematopoietic stem cell transplantation, Bone Marrow Transplant., 45, 772, 10.1038/bmt.2009.202 Aung, 2013, Incidence and natural history of pure red cell aplasia in major ABO-mismatched haematopoietic cell transplantation, Br J Haematol., 160, 798, 10.1111/bjh.12210 Marco-Ayala, 2021, Pure red cell aplasia after major or bidirectional ABO incompatible hematopoietic stem cell transplantation: to treat or not to treat, that is the question, Bone Marrow Transplant., 56, 769, 10.1038/s41409-020-01124-6 Stussi, 2009, Prevention of pure red cell aplasia after major or bidirectional ABO blood group incompatible hematopoietic stem cell transplantation by pretransplant reduction of host anti-donor isoagglutinins, Haematologica., 94, 239, 10.3324/haematol.13356 Holbro, 2015, Management of hemolytic anemia following allogeneic stem cell transplantation, Hematology Am Soc Hematol Educ Program., 2015, 378, 10.1182/asheducation-2015.1.378 Hill, 2017, Guidelines on the management of drug-induced immune and secondary autoimmune, haemolytic anaemia, Br J Haematol., 177, 208, 10.1111/bjh.14654 Silva, 1994, Synchronization of plasma exchange and cyclophosphamide in severe and refractory autoimmune hemolytic anemia, J Clin Apher., 9, 120, 10.1002/jca.2920090205 Santamaría, 1997, Successful treatment of pure red cell aplasia after major ABO-incompatible T cell-depleted bone marrow transplantation with erythropoietin, Bone Marrow Transplant., 20, 1105, 10.1038/sj.bmt.1701012 Busca, 2018, Eltrombopag for the treatment of refractory pure RBC aplasia after major ABO incompatible hematopoietic stem cell transplantation, Biol Blood Marrow Transplant., 24, 1765, 10.1016/j.bbmt.2018.04.022 Longval, 2021, Treatment for pure red cell aplasia after major ABO-incompatible allogeneic stem cell transplantation: a multicentre study, Br J Haematol., 193, 814, 10.1111/bjh.17463 Helbig, 2005, Successful treatment of pure red cell aplasia with repeated, low doses of rituximab in two patients after ABO-incompatible allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia, Haematologica., 90, ECR33 Audet, 2008, Passenger lymphocyte syndrome and liver transplantation, Clin Dev Immunol., 2008, 715769, 10.1155/2008/715769 Hess, 2018, Successful treatment of severe refractory autoimmune hemolytic anemia after hematopoietic stem cell transplant with abatacept, Transfusion., 58, 2122, 10.1111/trf.14907 Taniguchi, 1993, Recombinant human erythropoietin for long-term persistent anemia after major ABO-incompatible bone marrow transplantation, Bone Marrow Transplant., 12, 423 Liu, 2021, Eltrombopag restores erythropoiesis in refractory adult acquired pure red cell aplasia, Int J Hematol., 114, 124, 10.1007/s12185-021-03100-2 Selleri, 1998, CD34+-enriched donor lymphocyte infusions in a case of pure red cell aplasia and late graft failure after major ABO-incompatible bone marrow transplantation, Bone Marrow Transplant., 22, 605, 10.1038/sj.bmt.1701384 Fang, 2009, Mesenchymal stem cells for the treatment of refractory pure red cell aplasia after major ABO-incompatible hematopoietic stem cell transplantation, Ann Hematol., 88, 261, 10.1007/s00277-008-0599-0 Sergeevicheva, 2012, Rapid recovery from chronic PRCA by MSC infusion in patient after major ABO-mismatched alloSCT, Case Rep Med., 2012, 862721, 10.1155/2012/862721 Sackett, 2018, Successful treatment of pure red cell aplasia because of ABO major mismatched stem cell transplant, J Clin Apher., 33, 108, 10.1002/jca.21553 Poon, 2012, Successful treatment of isohemagglutinin-mediated pure red cell aplasia after ABO-mismatched allogeneic hematopoietic cell transplant using bortezomib, Bone Marrow Transplant., 47, 870, 10.1038/bmt.2011.176 Tolbert, 2016, Daratumumab is effective in the treatment of refractory post-transplant autoimmune hemolytic anemia: a pediatric case report [abstract], Blood., 128, XXX, 10.1182/blood.V128.22.4819.4819 Chapuy, 2018, Daratumumab for delayed red-cell engraftment after allogeneic transplantation, N Engl J Med., 379, 1846, 10.1056/NEJMoa1807438 Schuetz, 2018, Daratumumab in life-threatening autoimmune hemolytic anemia following hematopoietic stem cell transplantation, Blood Adv., 2, 2550, 10.1182/bloodadvances.2018020883 Blennerhassett, 2019, Post-allogeneic transplant Evans syndrome successfully treated with daratumumab, Br J Haematol., 187, e48, 10.1111/bjh.16171 Migdady, 2020, Successful treatment of thrombocytopenia with daratumumab after allogeneic transplant: a case report and literature review, Blood Adv., 4, 815, 10.1182/bloodadvances.2019001215 Chapuy, 2015, Resolving the daratumumab interference with blood compatibility testing, Transfusion., 55, 1545, 10.1111/trf.13069 van de Donk, 2019, Reprint of “Immunomodulatory effects of CD38-targeting antibodies”, Immunol Lett., 205, 71, 10.1016/j.imlet.2019.02.002 Krejcik, 2016, Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma, Blood., 128, 384, 10.1182/blood-2015-12-687749 Mócsai, 2010, The SYK tyrosine kinase: a crucial player in diverse biological functions, Nat Rev Immunol., 10, 387, 10.1038/nri2765 Kaur, 2013, Inhibitors of switch kinase ‘spleen tyrosine kinase’ in inflammation and immune-mediated disorders: a review, Eur J Med Chem., 67, 434, 10.1016/j.ejmech.2013.04.070 Poe, 2018, SYK inhibitor entospletinib prevents ocular and skin GVHD in mice, JCI Insight., 3, e122430, 10.1172/jci.insight.122430 Vo, 2020, A pilot trial of complement inhibition using eculizumab to overcome platelet transfusion refractoriness in human leukocyte antigen allo-immunized patients, Br J Haematol., 189, 551, 10.1111/bjh.16385 Gauchy, 2020, Efficacy of eculizumab in refractory life-threatening warm autoimmune hemolytic anemia associated with chronic myelomonocytic leukemia, Clin Case Rep., 8, 2641, 10.1002/ccr3.3250 Röth, 2018, Eculizumab in cold agglutinin disease (DECADE): an open-label, prospective, bicentric, nonrandomized phase 2 trial, Blood Adv., 2, 2543, 10.1182/bloodadvances.2018024190 Röth, 2021, Sutimlimab in cold agglutinin disease, N Engl J Med., 384, 1323, 10.1056/NEJMoa2027760 Hillmen, 2021, Pegcetacoplan versus eculizumab in paroxysmal nocturnal hemoglobinuria, N Engl J Med., 384, 1028, 10.1056/NEJMoa2029073 Frey, 2008, Graft-versus-host disease after donor leukocyte infusions: presentation and management, Best Pract Res Clin Haematol., 21, 205, 10.1016/j.beha.2008.02.007 Kollman, 2001, Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age, Blood., 98, 2043, 10.1182/blood.V98.7.2043 Seebach, 2005, ABO blood group barrier in allogeneic bone marrow transplantation revisited, Biol Blood Marrow Transplant., 11, 1006, 10.1016/j.bbmt.2005.07.015 Helming, 2007, ABO incompatible stem cell transplantation in children does not influence outcome, Pediatr Blood Cancer., 49, 313, 10.1002/pbc.21025 Michallet, 2008, Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year retrospective analysis from the Société Française de Greffe de Moelle et de Thérapie Cellulaire, Exp Hematol., 36, 535, 10.1016/j.exphem.2008.01.017 Kimura, 2008, Impact of AB0-blood group incompatibility on the outcome of recipients of bone marrow transplants from unrelated donors in the Japan Marrow Donor Program, Haematologica., 93, 1686, 10.3324/haematol.12933 Canaani, 2017, ABO incompatibility in mismatched unrelated donor allogeneic hematopoietic cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the EBMT, Am J Hematol., 92, 789, 10.1002/ajh.24771 Ataca Atilla, 2020, Effects of ABO incompatibility in allogeneic hematopoietic stem cell transplantation, Transfus Clin Biol., 27, 115, 10.1016/j.tracli.2020.06.008 Heim, 1988, Rh antibodies against the pretransplant red cells following Rh-incompatible bone marrow transplantation, Transfusion., 28, 272, 10.1046/j.1537-2995.1988.28388219159.x Tasaki, 1999, Multiple red blood cell antibodies produced by donor B lymphocytes after ABO-matched allogeneic bone marrow transplantation, Transfus Sci., 20, 121, 10.1016/S0955-3886(99)00020-X Izumi, 2003, Long-term production of pre-existing alloantibodies to E and c after allogenic BMT in a patient with aplastic anemia resulting in delayed hemolytic anemia, Transfusion., 43, 241, 10.1046/j.1537-2995.2003.00303.x Zupańska, 2005, Multiple red cell alloantibodies, including anti-Dib, after allogeneic ABO-matched peripheral blood progenitor cell transplantation, Transfusion., 45, 16, 10.1111/j.1537-2995.2005.04104.x Myser, 1986, A bone marrow transplant with an acquired anti-Le(a): a case study, Hum Immunol., 17, 102, 10.1016/0198-8859(86)90080-7